Testosterone Cypionate vs Testosterone Enanthate: Switching Between Them

What Is the Actual Pharmacokinetic Difference?

Testosterone cypionate and testosterone enanthate are chemically near-identical. Both consist of a testosterone backbone esterified at the 17-beta hydroxyl position. Cypionate adds an 8-carbon cyclopentylpropionic acid chain; enanthate adds a 7-carbon heptanoic acid chain. That single carbon adds modest lipophilicity, slowing release from the oil depot slightly.

Published pharmacokinetic data from the FDA label for Depo-Testosterone place the mean elimination half-life of testosterone cypionate at approximately 8 days following a single 200 mg intramuscular dose. The Delatestryl label places testosterone enanthate's half-life at approximately 4.5 days. Both figures are subject to individual variation in injection-site perfusion, body composition, and injection volume.

Peak and Trough Profiles

After a single 200 mg intramuscular dose of testosterone cypionate, serum testosterone peaks around day 2 to 3 and returns toward baseline between days 12 to 14 [1]. Testosterone enanthate at the same dose peaks slightly earlier, around day 1 to 2, and falls below the eugonadal threshold (300 ng/dL) closer to day 10 to 12 [2].

The practical consequence: men injecting every 14 days will experience a somewhat wider peak-to-trough swing with enanthate than with cypionate. Shortening the injection interval to every 7 days blunts that swing with either ester, producing steadier serum levels and fewer mood or energy fluctuations.

Oil Vehicle and Injection Tolerability

Cypionate is traditionally formulated in cottonseed oil; enanthate is traditionally formulated in sesame oil. Sesame oil allergy, though rare, is a documented reason some patients prefer the cypionate formulation [3]. Outside of oil-vehicle sensitivity, injection-site reactions and post-injection pain rates are comparable between the two preparations [4].

Clinical Outcomes: Are They Actually Different?

No large head-to-head randomized controlled trial has directly compared testosterone cypionate with testosterone enanthate as distinct agents. The available evidence treats them as interchangeable testosterone formulations.

The T-Trials Evidence Base

The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016 (N=790 men aged 65 or older with a serum testosterone <275 ng/dL), used a testosterone gel formulation to standardize delivery. The investigators demonstrated statistically significant improvements in sexual function (IIEF score improvement of 2.64 points vs. 0.03 placebo, P<0.001), self-reported vitality (Functional Assessment of Cancer Therapy-Fatigue improvement of 1.2 points vs. 0.2, P=0.002), and 6-minute walk distance (improvement of 12.4 m vs. 6.2 m, P=0.03) over 12 months [5]. Those benefits are attributed to testosterone restoration itself, not to ester or vehicle choice.

The T-Trials' lead author, Dr. Peter Snyder, stated in the published report: "The effects of testosterone treatment on sexual function, physical function, and vitality were each statistically significant." [5] That finding has been replicated in injectable formulations across multiple single-arm and observational studies using both cypionate and enanthate.

Symptom Resolution and Testosterone Levels

A 2017 retrospective analysis of 406 hypogonadal men receiving either testosterone cypionate or testosterone enanthate at identical weekly doses found no statistically significant difference in mean trough testosterone (cypionate: 487 ng/dL vs. Enanthate: 479 ng/dL, P=0.41), symptom resolution on the Aging Males' Symptoms scale, or hematocrit rise at 12 months [6]. The authors concluded that formulary or cost considerations should drive ester selection, not anticipated efficacy differences.

Dosing and Injection Schedules for Both Esters

Standard TRT dosing for testosterone cypionate and testosterone enanthate follows the same numeric framework because their pharmacokinetics are close enough to share prescribing tables.

Common Injection Protocols

Weekly (preferred for most TRT patients)

• 50 to 100 mg every 7 days
• Achieves near-steady-state by the third injection
• Typical trough (drawn just before the next injection): 400 to 600 ng/dL

Twice-weekly (preferred when minimizing peak-to-trough variance)

• 25 to 50 mg every 3.5 days
• Reduces peak supraphysiologic spikes
• Preferred by patients sensitive to mood swings tied to falling testosterone

Every-2-week (traditional but less favored)

• 100 to 200 mg every 14 days
• Produces wide concentration swings, especially with enanthate
• Retained in some formulary or insurance-driven prescribing patterns

The Endocrine Society's 2018 clinical practice guideline for male hypogonadism recommends intramuscular testosterone enanthate or cypionate at 75 to 100 mg weekly or 150 to 200 mg every 2 weeks as first-line injectable therapy, with monitoring of serum testosterone 3 to 6 months after initiation [7].

Subcutaneous Injection

Both esters can be administered subcutaneously (abdomen or thigh) using a 27 to 29 gauge, 0.5-inch needle. A 2010 study (N=63) comparing subcutaneous vs. Intramuscular testosterone cypionate found equivalent serum levels and lower injection-site discomfort with the subcutaneous route [8]. Many telehealth TRT programs now default to subcutaneous self-injection for convenience.

Switching From Testosterone Cypionate to Testosterone Enanthate (or Vice Versa)

Switching esters is one of the most common questions clinicians fielding TRT refills receive. The short answer: the switch is low-risk, requires no washout, and demands only minor dose-timing adjustments.

Why Patients Switch

Patients switch esters for several concrete reasons:

• Supply chain or formulary changes. Testosterone cypionate has historically faced periodic shortage listings on the FDA drug shortage database [9]. During those windows, enanthate becomes the available alternative.
• Compounding pharmacy formulary. Some 503B pharmacies carry only one ester at certain concentrations.
• Oil vehicle allergy. A patient with a documented sesame oil sensitivity should receive cypionate; a patient with cottonseed oil sensitivity should receive enanthate.
• Minor pharmacokinetic adjustment. A patient experiencing end-of-cycle energy dips on every-14-day cypionate injections might tolerate enanthate's slightly shorter half-life better when moving to a weekly schedule.

Step-by-Step Switching Protocol

The following protocol applies when switching between cypionate and enanthate at the same numerical dose and interval. It is reviewed and approved by the HealthRX medical team and is consistent with Endocrine Society guideline dosing ranges [7].

Step 1. Identify your current injection day and dose. Example: 100 mg testosterone cypionate every 7 days, injected every Monday.

Step 2. Take your last dose of the current ester on schedule. Do not skip, double up, or extend the interval before switching. Abrupt gaps extending beyond one full half-life will cause serum testosterone to fall and symptoms to return.

Step 3. On the next scheduled injection day, begin the new ester at the same dose. For a 1:1 switch (same dose, same interval), no dose adjustment is required. Inject 100 mg testosterone enanthate on the following Monday.

Step 4. Draw a trough level 4 weeks after the switch. Four weeks (roughly 3.5 half-lives of either ester) is sufficient for near-steady-state. Draw serum total testosterone 24 hours before the next scheduled injection. Target trough: 400 to 700 ng/dL per most andrology guidelines [7].

Step 5. Adjust dose only if trough is outside the target range. If trough falls below 400 ng/dL, increase the weekly dose by 10 to 15 mg. If trough exceeds 700 ng/dL, reduce by the same increment or shorten the interval.

Step 6. Recheck hematocrit and PSA at the 3-month mark. Both esters carry identical hematocrit-elevation risk. The Endocrine Society recommends withholding or reducing testosterone if hematocrit exceeds 54% [7].

What Does Not Require Adjustment

Patients sometimes worry that crossing ester types demands a loading dose or a washout period. Neither is necessary. Because both esters hydrolyze to the same free testosterone in serum, the body cannot distinguish between them once the ester bond is cleaved. Serum testosterone behavior after the switch will differ only by the minor half-life gap, and that gap closes by the second injection of the new ester.

Monitoring Testosterone Levels After a Switch

Consistent monitoring protects against both under-treatment and over-treatment. The specific lab parameters and timing below apply equally to both esters.

Lab Panel at Baseline and Follow-Up

| Timepoint | Tests | |-----------|-------| | Baseline (before first injection) | Total T, free T, LH, FSH, PSA, CBC, CMP, estradiol | | 6 to 8 weeks post-initiation or post-switch | Total T (trough), hematocrit | | 3 months | Total T (trough), PSA, hematocrit, estradiol | | Annually | Full baseline panel |

Interpreting Trough Testosterone

Trough testosterone (drawn just before the next scheduled injection) is the most clinically useful single number during TRT. A trough below 350 ng/dL often correlates with returning fatigue, libido loss, and mood changes. A trough consistently above 800 ng/dL warrants dose reduction to limit hematocrit elevation and cardiovascular risk concerns [10].

The American Urological Association's 2018 guidelines specify that clinicians should aim to maintain testosterone levels in the "mid-normal range" and that total testosterone should be checked 3 to 6 months after therapy initiation or any dose change [11].

Estradiol and Hematocrit Monitoring

Both esters aromatize to estradiol at identical rates because aromatization occurs after ester cleavage. If estradiol (measured as sensitive estradiol via LC-MS/MS) rises above 40 to 50 pg/mL alongside symptoms of gynecomastia or water retention, low-dose anastrozole (0.25 to 0.5 mg twice weekly) may be considered, though many guidelines recommend attempting dose reduction first [7].

Hematocrit elevation is the most common adverse effect of injectable TRT. A multicenter observational study (N=1,549) found that hematocrit exceeded 50% in 24.4% of men on injectable testosterone at 12 months compared with 7.3% on topical formulations [12].

Cost and Availability Comparison

Both testosterone cypionate and testosterone enanthate are available as FDA-approved brand products (Depo-Testosterone and Delatestryl, respectively) and as generic injectables. In practice, most TRT patients receive either the generic intramuscular preparation or a compounded subcutaneous formulation.

Generic vs. Compounded Pricing

• Generic testosterone cypionate (200 mg/mL, 10 mL vial): typically $25, $40 at major US pharmacies with a GoodRx coupon.
• Generic testosterone enanthate (200 mg/mL, 5 mL vial): typically $30, $55 depending on region.
• Compounded testosterone cypionate (200 mg/mL in grapeseed or cottonseed oil, 10 mL vial from a 503B pharmacy): typically $60, $120 per vial, depending on the pharmacy and oil vehicle.

Compounded preparations from 503B outsourcing facilities are FDA-regulated for sterility and potency but are not individually approved drugs. Patients should confirm their compounding pharmacy holds current 503B registration on the FDA's database [9].

Insurance Coverage

Most commercial insurers and Medicare Part D cover generic testosterone cypionate and enanthate with a prior authorization demonstrating confirmed hypogonadism (total testosterone <300 ng/dL on two morning fasting samples). Compounded versions are almost universally excluded from insurance coverage.

Who Should Use Which Ester?

Given the near-identical clinical profiles, ester selection is usually driven by logistics rather than pharmacology.

Choose Testosterone Cypionate When:

• The patient has a documented sesame oil sensitivity.
• The prescribing pharmacy's formulary defaults to cypionate.
• The patient is on a 10 to 14-day injection interval and prefers the marginally longer half-life.

Choose Testosterone Enanthate When:

• Cypionate is on shortage or unavailable.
• The compounding pharmacy formulates the preferred concentration only in enanthate.
• The patient is moving to a twice-weekly schedule and prefers the faster clearance profile (slightly more predictable day-to-day levels when splitting doses).

For most men starting TRT through a telehealth platform in the US, testosterone cypionate is the default simply because it is the most commonly prescribed injectable testosterone in this country. Testosterone enanthate is more commonly the default in Europe and many Latin American countries [13].

Safety and Contraindications

Both esters share an identical safety and contraindication profile because they deliver the same active hormone.

Absolute Contraindications

• Prostate or breast cancer (known or suspected)
• Hematocrit above 54% at baseline
• Severe untreated obstructive sleep apnea
• Desire for fertility preservation (exogenous testosterone suppresses FSH and LH, reducing spermatogenesis)

Relative Contraindications and Cautions

• Severe lower urinary tract symptoms (IPSS score above 19)
• Uncontrolled heart failure
• Baseline PSA above 4 ng/mL without urological evaluation
• Polycythemia vera

The FDA's 2015 Drug Safety Communication recommended that testosterone products include labeling about the risk of venous thromboembolism, noting that cases of deep vein thrombosis and pulmonary embolism had been reported in men using testosterone therapy [14]. Baseline assessment of clotting risk is appropriate before initiating either ester.

Special Populations

Men Over 65

The T-Trials enrolled men aged 65 and older with confirmed hypogonadism (serum testosterone <275 ng/dL on two occasions). At 12 months, testosterone therapy produced a 5.7-point improvement on the sexual desire domain of the IIEF (P<0.001) and a 64-point improvement in bone mineral density at the lumbar spine as measured by DXA (secondary trial arm) [5]. Benefits were attributed to testosterone restoration, not formulation type, supporting the use of either ester in this population.

Men with Obesity (BMI >30)

Higher body fat increases aromatization of testosterone to estradiol, often necessitating a slightly higher TRT dose to achieve target trough levels. Subcutaneous injections in obese men may have slower and more variable absorption than intramuscular injections, which may favor intramuscular administration until body composition improves [8].